Objective: To assess the onset of ocrelizumab efficacy on brain magnetic resonance imaging (MRI) measures of disease activity in the Phase II study in relapsing-remitting multiple sclerosis (RRMS), an
Classification results in% (6-fold cross-validation, 100 runs) obtained separating TBI patients with a severe disability from patients with low disability outcome based on structural volume changes be
